Elicio Therapeutics and Angion enter into merger agreement to advance cancer vaccine

Checkpoint therapy breakthrough sparks new vaccine

Immune-checkpoint therapy, which attempts to harness a patient’s own immune system to fight cancer, has revolutionized cancer care over the past two decades.

September 12, 2025

Vol.51 No.33

Capitol Hill

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Cancer Policy

The departure (and return) of Vinay Prasad

At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

Clinical Roundup

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.

September 05, 2025

Vol.51 No.32

Cancer Policy

HHS halts nearly $500M in mRNA-related vaccine contracts

The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.

August 08, 2025

Vol.51 No.31

By Claire Marie Porter

Elicio Therapeutics and Angion enter into merger agreement to advance cancer vaccine

YOU MAY BE INTERESTED IN

Checkpoint therapy breakthrough sparks new vaccine

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

HHS halts nearly $500M in mRNA-related vaccine contracts

Renew today!

Subscriber content

Never miss an issue!

Login

Elicio Therapeutics and Angion enter into merger agreement to advance cancer vaccine

YOU MAY BE INTERESTED IN

Checkpoint therapy breakthrough sparks new vaccine

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearingKennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

The departure (and return) of Vinay Prasad

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

HHS halts nearly $500M in mRNA-related vaccine contracts

Never miss an issue!

Login

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”